SIMILAR PATTERNS OF AMINO ACIDS FOR 3QXV_D_MTXD2000_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1g6v	ANTIBODY HEAVY CHAIN (Camelus dromedarius)	PF07686 (V-set)	5	VAL K 802 ALA K 824 MET K 834 VAL K 877 TYR K 915	None	0.69A	3qxvD-1g6vK: 20.1	3qxvD-1g6vK: 69.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1i3u	ANTIBODY VHH LAMA DOMAIN (Lama glama)	PF07686 (V-set)	5	ALA A 24 ARG A 77 VAL A 84 ALA A 103 TYR A 118	None None None None CGN A 1 ( 4.0A)	0.84A	3qxvD-1i3uA: 20.8	3qxvD-1i3uA: 59.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1kxt	IMMUNOGLOBULIN VHH FRAGMENT (Camelus dromedarius)	PF07686 (V-set)	5	VAL B 2 ALA B 24 MET B 34 ALA B 94 TYR B 102	None	0.98A	3qxvD-1kxtB: 19.2	3qxvD-1kxtB: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1pz5	HEAVY CHAIN OF FAB (SYA/J6) (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL B 2 ALA B 24 MET B 34 ARG B 71 VAL B 78	None	0.79A	3qxvD-1pz5B: 19.9	3qxvD-1pz5B: 51.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1t3q	QUINOLINE 2-OXIDOREDUCTASE LARGE SUBUNIT (Pseudomonas putida)	PF01315 (Ald_Xan_dh_C) PF02738 (Ald_Xan_dh_C2)	5	ALA B 314 ARG B 416 SER B 354 ARG B 188 VAL B 186	None	0.93A	3qxvD-1t3qB: undetectable	3qxvD-1t3qB: 10.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t66	IMMUNOGLOBULIN HEAVY CHAIN (Mus musculus)	no annotation	5	ALA H 24 MET H 34 ARG H 74 VAL H 81 TYR H 107	None	0.79A	3qxvD-1t66H: 19.3	3qxvD-1t66H: 31.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t66	IMMUNOGLOBULIN HEAVY CHAIN (Mus musculus)	no annotation	5	VAL H 2 MET H 34 ARG H 74 VAL H 81 TYR H 107	None	0.76A	3qxvD-1t66H: 19.3	3qxvD-1t66H: 31.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2x6m	HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY (Camelus dromedarius)	PF07686 (V-set)	5	ALA A 24 MET A 34 VAL A 80 ALA A 99 TYR A 115	None	0.66A	3qxvD-2x6mA: 21.1	3qxvD-2x6mA: 70.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xa3	LLAMA HEAVY CHAIN ANTIBODY D7 (Lama glama)	PF07686 (V-set)	5	SER A 29 MET A 34 VAL A 78 ALA A 94 TYR A 102	SO4 A1114 (-2.7A) None None None None	0.68A	3qxvD-2xa3A: 20.8	3qxvD-2xa3A: 69.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3g9a	MINIMIZER (Camelus dromedarius)	PF07686 (V-set)	7	VAL B 2 ALA B 24 MET B 34 ARG B 71 VAL B 78 ALA B 94 TYR B 102	None	0.83A	3qxvD-3g9aB: 19.5	3qxvD-3g9aB: 64.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3if1	IMMUNOGLOBULIN HEAVY CHAIN (IGG2A) (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL B 2 ALA B 24 MET B 34 ARG B 71 TYR B 102	None	0.70A	3qxvD-3if1B: 19.5	3qxvD-3if1B: 32.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3k7u	ANTIBODY (Lama glama)	PF07686 (V-set)	5	MET A 34 ARG A 72 VAL A 79 ALA A 98 TYR A 111	None	0.39A	3qxvD-3k7uA: 21.9	3qxvD-3k7uA: 73.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ln9	IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN B10 (Camelidae)	PF07686 (V-set)	5	ALA A 24 ARG A 72 VAL A 79 ALA A 98 TYR A 113	None None None None GOL A 137 (-4.8A)	0.77A	3qxvD-3ln9A: 19.2	3qxvD-3ln9A: 67.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	6	SER A 30 TRP A 34 MET A 36 VAL A 81 ALA A 100 TYR A 120	None	1.48A	3qxvD-3qxuA: 24.0	3qxvD-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	7	SER A 31 TRP A 34 MET A 36 ARG A 74 VAL A 81 ALA A 100 TYR A 120	None	1.40A	3qxvD-3qxuA: 24.0	3qxvD-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	7	VAL A 4 ALA A 26 SER A 30 MET A 36 VAL A 81 ALA A 100 TYR A 120	None	0.90A	3qxvD-3qxuA: 24.0	3qxvD-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	8	VAL A 4 ALA A 26 SER A 31 MET A 36 ARG A 74 VAL A 81 ALA A 100 TYR A 120	None	0.88A	3qxvD-3qxuA: 24.0	3qxvD-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qyc	VH DOMAIN OF IGG MOLECULE (Homo sapiens)	PF07686 (V-set)	5	VAL A 4 ALA A 26 MET A 36 ARG A 74 VAL A 81	None	0.69A	3qxvD-3qycA: 19.8	3qxvD-3qycA: 61.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3r0m	LLAMA VHH A12 (Lama glama)	PF07686 (V-set)	5	ALA A 24 SER A 29 MET A 34 VAL A 78 ALA A 94	None SO4 A 131 (-2.7A) None None None	0.94A	3qxvD-3r0mA: 21.2	3qxvD-3r0mA: 70.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3stb	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	5	ALA A 26 MET A 36 ARG A 73 VAL A 80 ALA A 99	None	0.65A	3qxvD-3stbA: 22.0	3qxvD-3stbA: 70.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tpk	IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN KW1 (Camelidae)	PF07686 (V-set)	5	VAL A 2 ALA A 24 VAL A 79 ALA A 98 TYR A 110	None BEN A 133 (-3.6A) BEN A 133 (-4.6A) BEN A 133 ( 4.2A) None	0.92A	3qxvD-3tpkA: 20.3	3qxvD-3tpkA: 64.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aq1	NBKB6 (Lama glama)	PF07686 (V-set)	5	MET B 34 ARG B 72 VAL B 79 ALA B 98 TYR B 113	None	0.97A	3qxvD-4aq1B: 21.8	3qxvD-4aq1B: 74.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4b41	ANTIBODY G7 (Lama glama)	PF07686 (V-set)	5	VAL A 2 ALA A 24 MET A 34 VAL A 78 ALA A 97	None	0.90A	3qxvD-4b41A: 18.6	3qxvD-4b41A: 72.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dka	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	7	VAL A 2 ALA A 24 MET A 34 ARG A 72 VAL A 79 ALA A 98 TYR A 116	None	0.81A	3qxvD-4dkaA: 22.0	3qxvD-4dkaA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4eig	CA1698 CAMEL ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	6	ALA B 24 MET B 34 ARG B 71 VAL B 78 ALA B 97 TYR B 106	None	0.72A	3qxvD-4eigB: 20.2	3qxvD-4eigB: 66.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fhb	NB179 (Lama glama)	PF07686 (V-set)	5	MET D 34 ARG D 72 VAL D 79 ALA D 98 TYR D 118	None	0.60A	3qxvD-4fhbD: 21.2	3qxvD-4fhbD: 71.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gft	NANOBODY (Lama glama)	PF07686 (V-set)	5	MET B 36 ARG B 74 VAL B 81 ALA B 100 TYR B 115	None None None None PCA B 2 ( 3.9A)	0.38A	3qxvD-4gftB: 22.0	3qxvD-4gftB: 66.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hem	ANTI-BASEPLATE TP901-1 LLAMA VHH 02 (Lama glama)	PF07686 (V-set)	6	ALA E 24 MET E 34 ARG E 72 VAL E 79 ALA E 98 TYR E 112	None	0.64A	3qxvD-4hemE: 22.6	3qxvD-4hemE: 73.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hlz	FAB C179 HEAVY CHAIN (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL G 2 MET G 34 ARG G 71 VAL G 78 TYR G 102	None	0.78A	3qxvD-4hlzG: 19.0	3qxvD-4hlzG: 53.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hxa	13D9 FAB HEAVY CHAIN (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 MET H 34 ARG H 71 VAL H 78 TYR H 102	None	0.90A	3qxvD-4hxaH: 20.6	3qxvD-4hxaH: 53.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4krm	NANOBODY/VHH DOMAIN 7D12 (Lama glama)	PF07686 (V-set)	6	ALA B 24 MET B 34 ARG B 72 VAL B 79 ALA B 98 TYR B 113	None	0.71A	3qxvD-4krmB: 23.3	3qxvD-4krmB: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4krm	NANOBODY/VHH DOMAIN 7D12 (Lama glama)	PF07686 (V-set)	5	SER B 29 MET B 34 VAL B 79 ALA B 98 TYR B 113	None	0.98A	3qxvD-4krmB: 23.3	3qxvD-4krmB: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lde	CAMELID ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	5	VAL B 2 ALA B 24 ARG B 71 VAL B 78 TYR B 109	None	0.91A	3qxvD-4ldeB: 19.3	3qxvD-4ldeB: 68.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lde	CAMELID ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	5	VAL B 2 MET B 34 ARG B 71 VAL B 78 TYR B 109	None	0.77A	3qxvD-4ldeB: 19.3	3qxvD-4ldeB: 68.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lhq	CAMELID NANOBODY (Vicugna pacos)	PF07686 (V-set)	5	ALA B 24 SER B 28 MET B 34 ARG B 72 VAL B 79	None	0.83A	3qxvD-4lhqB: 21.5	3qxvD-4lhqB: 63.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4mqt	NANOBODY 9-8 (Lama glama)	PF07686 (V-set)	5	VAL B 2 ALA B 24 VAL B 82 ALA B 101 TYR B 110	None	0.81A	3qxvD-4mqtB: 19.2	3qxvD-4mqtB: 64.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4n1h	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-F11N (Lama glama)	PF07686 (V-set)	5	ALA B 24 MET B 34 ARG B 72 VAL B 79 ALA B 98	None	0.81A	3qxvD-4n1hB: 21.3	3qxvD-4n1hB: 68.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc1	A20.1 VHH (Lama glama)	PF07686 (V-set)	7	VAL C 9 ALA C 31 MET C 41 ARG C 79 VAL C 86 ALA C 105 TYR C 119	None	0.90A	3qxvD-4nc1C: 22.0	3qxvD-4nc1C: 70.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc2	B39 VHH (Lama glama)	PF07686 (V-set)	5	ALA B 24 MET B 34 ARG B 71 ALA B 97 TYR B 111	None	0.75A	3qxvD-4nc2B: 22.8	3qxvD-4nc2B: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc2	B39 VHH (Lama glama)	PF07686 (V-set)	5	VAL B 2 MET B 34 ARG B 71 ALA B 97 TYR B 111	None	0.63A	3qxvD-4nc2B: 22.8	3qxvD-4nc2B: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2c	NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	6	VAL G 2 MET G 34 ARG G 71 VAL G 78 ALA G 97 TYR G 111	None	0.62A	3qxvD-4p2cG: 19.1	3qxvD-4p2cG: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p49	ANTIBODY SCFV B8 (Gallus gallus)	PF07686 (V-set)	5	VAL A 122 ALA A 144 MET A 154 ARG A 193 VAL A 200	None	0.91A	3qxvD-4p49A: 21.7	3qxvD-4p49A: 51.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4pb0	AB53 HEAVY CHAIN (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 ALA H 24 MET H 34 ARG H 71 VAL H 78	CL H 303 (-4.4A) None None None None	0.93A	3qxvD-4pb0H: 18.7	3qxvD-4pb0H: 32.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qlr	LLAMA NANOBODY N02 VH DOMAIN (Lama glama)	PF07686 (V-set)	5	ALA A 24 ARG A 72 VAL A 79 ALA A 98 TYR A 113	None	0.76A	3qxvD-4qlrA: 22.4	3qxvD-4qlrA: 69.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qo1	NB139 NANOBODY AGAINST THE DNA-BINDING DOMAIN OF P53 (Lama glama)	PF07686 (V-set)	6	ALA A 25 MET A 35 ARG A 73 VAL A 80 ALA A 99 TYR A 113	None	0.57A	3qxvD-4qo1A: 21.2	3qxvD-4qo1A: 62.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4tvs	VHH DOMAIN BS-1 (Vicugna pacos)	PF05609 (LAP1C)	5	ALA a 25 ARG a 73 VAL a 80 ALA a 99 TYR a 117	None	0.79A	3qxvD-4tvsa: 22.1	3qxvD-4tvsa: 72.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4w6y	NANOBODY NBFEDF9 (Lama glama)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 VAL B 79 ALA B 98 TYR B 118	None	0.92A	3qxvD-4w6yB: 21.0	3qxvD-4w6yB: 69.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4weu	ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	6	VAL D 802 ALA D 824 MET D 834 ARG D 872 ALA D 898 TYR D 910	None	0.68A	3qxvD-4weuD: 22.3	3qxvD-4weuD: 72.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4x8j	12F4 FAB HEAVY CHAIN (Mus musculus)	no annotation	5	VAL H 2 MET H 34 ARG H 74 VAL H 81 TYR H 104	None None None None 2PE H 302 ( 4.6A)	0.67A	3qxvD-4x8jH: 15.5	3qxvD-4x8jH: 33.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xt1	NANOBODY 7 (Vicugna pacos)	PF07686 (V-set)	6	VAL C 2 ALA C 24 MET C 34 VAL C 78 ALA C 97 TYR C 107	None	0.87A	3qxvD-4xt1C: 19.0	3qxvD-4xt1C: 68.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5a2k	IG LAMBDA-1 CHAIN V REGION S43 (Mus musculus)	PF07686 (V-set)	6	VAL H 2 ALA H 24 MET H 34 ARG H 71 VAL H 78 TYR H 102	None	0.79A	3qxvD-5a2kH: 19.8	3qxvD-5a2kH: 29.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5aum	HEAVY CHAIN OF FAB FRAGMENT (Rattus)	no annotation	5	ALA H 24 MET H 34 ARG H 71 VAL H 78 ALA H 94	None	0.67A	3qxvD-5aumH: 19.7	3qxvD-5aumH: 38.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5aum	HEAVY CHAIN OF FAB FRAGMENT (Rattus)	no annotation	5	VAL H 2 MET H 34 ARG H 71 VAL H 78 ALA H 94	None	0.58A	3qxvD-5aumH: 19.7	3qxvD-5aumH: 38.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e1h	F8(JOB10) VHH ANTIBODY (Vicugna pacos)	PF07686 (V-set)	5	VAL B 2 ALA B 24 MET B 34 ARG B 72 VAL B 79	None	0.83A	3qxvD-5e1hB: 20.3	3qxvD-5e1hB: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e7f	NANOBODY L06 (Camelus dromedarius)	PF07686 (V-set)	5	VAL A 4 MET A 36 ARG A 73 VAL A 80 ALA A 99	None	0.72A	3qxvD-5e7fA: 18.4	3qxvD-5e7fA: 66.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fwo	NANOBODY (Lama glama)	PF07686 (V-set)	6	VAL A 2 ALA A 24 MET A 34 ARG A 71 VAL A 78 TYR A 102	None	0.87A	3qxvD-5fwoA: 21.5	3qxvD-5fwoA: 68.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fwo	NANOBODY (Lama glama)	PF07686 (V-set)	6	VAL A 2 MET A 34 ARG A 71 VAL A 78 ALA A 94 TYR A 102	None	0.62A	3qxvD-5fwoA: 21.5	3qxvD-5fwoA: 68.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5gxb	NANOBODY (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 VAL B 79 ALA B 98 TYR B 118	None	1.09A	3qxvD-5gxbB: 20.9	3qxvD-5gxbB: 68.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hm1	LAMA VHH ANTIBODY 2E7 (Lama glama)	PF07686 (V-set)	5	VAL A 2 ALA A 24 VAL A 78 ALA A 94 TYR A 102	None	0.69A	3qxvD-5hm1A: 18.7	3qxvD-5hm1A: 68.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hvf	VHH-I83 (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 ARG B 70 VAL B 77 ALA B 96 TYR B 108	None	0.86A	3qxvD-5hvfB: 18.5	3qxvD-5hvfB: 69.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hvf	VHH-I83 (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 VAL B 77 ALA B 96 TYR B 108	None	0.95A	3qxvD-5hvfB: 18.5	3qxvD-5hvfB: 69.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5iml	NANOBODY (Camelidae)	PF07686 (V-set)	6	ALA B 23 MET B 33 ARG B 71 VAL B 78 ALA B 97 TYR B 113	None	0.75A	3qxvD-5imlB: 23.6	3qxvD-5imlB: 75.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j1s	VHH DOMAIN BS-2 (Vicugna pacos)	PF07686 (V-set)	7	VAL C 3 ALA C 25 MET C 35 ARG C 72 VAL C 79 ALA C 98 TYR C 112	None	0.88A	3qxvD-5j1sC: 19.5	3qxvD-5j1sC: 66.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j56	VHH SINGLE CHAIN ANTIBODY V1C7 (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 ARG B 76 VAL B 83 ALA B 102 TYR B 117	None	0.91A	3qxvD-5j56B: 20.7	3qxvD-5j56B: 67.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ja9	NANOBODY 6 (Lama glama)	PF07686 (V-set)	5	VAL A 3 ALA A 25 MET A 35 ARG A 73 ALA A 99	None	0.93A	3qxvD-5ja9A: 20.2	3qxvD-5ja9A: 68.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5jqh	NANOBODY60, NB60 (Lama glama)	no annotation	5	VAL D 2 MET D 34 ARG D 71 VAL D 78 ALA D 97	None	0.95A	3qxvD-5jqhD: 19.2	3qxvD-5jqhD: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5kel	C2G4 VARIABLE FAB DOMAIN HEAVY CHAIN (Homo sapiens)	PF07686 (V-set)	6	VAL H 2 ALA H 24 MET H 34 ARG H 71 VAL H 78 TYR H 102	None	0.99A	3qxvD-5kelH: 17.1	3qxvD-5kelH: 51.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lhq	CAMELID-DERIVED ANTIBODY FRAGMENT NB7 (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 ARG B 72 VAL B 79 ALA B 98 TYR B 122	None	0.62A	3qxvD-5lhqB: 21.6	3qxvD-5lhqB: 64.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lmj	NANOBODY (Lama glama)	PF07686 (V-set)	6	ALA A 24 MET A 34 ARG A 71 VAL A 78 ALA A 94 TYR A 102	None	0.95A	3qxvD-5lmjA: 20.2	3qxvD-5lmjA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lmj	NANOBODY (Lama glama)	PF07686 (V-set)	6	VAL A 2 ALA A 24 ARG A 71 VAL A 78 ALA A 94 TYR A 102	None	0.95A	3qxvD-5lmjA: 20.2	3qxvD-5lmjA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lwf	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S (Lama glama)	no annotation	6	ALA C 27 MET C 37 ARG C 75 VAL C 82 ALA C 101 TYR C 117	None None None None None ACT C 202 (-4.4A)	0.59A	3qxvD-5lwfC: 21.3	3qxvD-5lwfC: 68.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lwf	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S (Lama glama)	no annotation	5	VAL C 5 ARG C 75 VAL C 82 ALA C 101 TYR C 117	None None None None ACT C 202 (-4.4A)	0.86A	3qxvD-5lwfC: 21.3	3qxvD-5lwfC: 68.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5m13	SYNTHETIC NANOBODY L2_C06 (A-MBP#2) (synthetic construct)	no annotation	5	VAL B 2 ALA B 24 VAL B 79 ALA B 98 TYR B 114	None	0.93A	3qxvD-5m13B: 21.8	3qxvD-5m13B: 63.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5mwn	LLAMA NANOBODY RAISED AGAINST TSSK, NBK27 (Lama glama)	PF07686 (V-set)	5	VAL N 2 ALA N 24 ARG N 71 VAL N 78 ALA N 97	None	0.94A	3qxvD-5mwnN: 18.3	3qxvD-5mwnN: 67.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5mwn	LLAMA NANOBODY RAISED AGAINST TSSK, NBK27 (Lama glama)	PF07686 (V-set)	5	VAL N 2 ALA N 24 MET N 34 VAL N 78 ALA N 97	None	0.95A	3qxvD-5mwnN: 18.3	3qxvD-5mwnN: 67.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o02	NANOBODY (VHH) NANO-4 (Vicugna pacos)	PF07686 (V-set)	5	VAL C 2 MET C 34 ARG C 72 ALA C 98 TYR C 113	None	0.66A	3qxvD-5o02C: 21.3	3qxvD-5o02C: 68.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o03	NANOBODY (VHH) NANO-32 (Norwalk virus)	PF07686 (V-set)	5	ALA C 24 ARG C 72 VAL C 79 ALA C 98 TYR C 124	None	0.88A	3qxvD-5o03C: 20.3	3qxvD-5o03C: 63.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o04	NANOBODY (VHH) NANO-26 (Vicugna pacos)	PF07686 (V-set)	5	VAL E 2 ALA E 24 ARG E 71 VAL E 78 TYR E 104	None	0.83A	3qxvD-5o04E: 18.7	3qxvD-5o04E: 65.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o05	NANOBODY (VHH) NANO-42 (Vicugna pacos)	PF07686 (V-set)	5	VAL C 2 ALA C 24 SER C 29 VAL C 78 TYR C 109	None	0.90A	3qxvD-5o05C: 17.1	3qxvD-5o05C: 67.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o8f	NANOBODY NB25 (Lama glama)	no annotation	5	MET L 34 ARG L 72 VAL L 79 ALA L 98 TYR L 114	None	0.62A	3qxvD-5o8fL: 21.4	3qxvD-5o8fL: 68.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5uk4	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	6	VAL p 2 MET p 34 ARG p 72 VAL p 79 ALA p 98 TYR p 114	None	0.76A	3qxvD-5uk4p: 21.4	3qxvD-5uk4p: 71.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ukb	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	5	ALA d 24 ARG d 72 VAL d 79 ALA d 98 TYR d 113	None	0.74A	3qxvD-5ukbd: 22.3	3qxvD-5ukbd: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vgj	VRC38.01 FAB HEAVY CHAIN (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 ALA H 24 MET H 34 ARG H 71 VAL H 78	None	0.69A	3qxvD-5vgjH: 19.1	3qxvD-5vgjH: 36.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxj	SINGLE-DOMAIN ANTIBODY JMK-E3 (Vicugna pacos)	no annotation	6	VAL B 2 MET B 34 ARG B 72 VAL B 79 ALA B 98 TYR B 108	None	0.78A	3qxvD-5vxjB: 19.2	3qxvD-5vxjB: 63.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxl	SINGLE-DOMAIN ANTIBODY JPS-G3 (Vicugna pacos)	no annotation	5	ALA B 24 MET B 34 ARG B 73 ALA B 99 TYR B 106	None	0.69A	3qxvD-5vxlB: 20.2	3qxvD-5vxlB: 66.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxl	SINGLE-DOMAIN ANTIBODY JPS-G3 (Vicugna pacos)	no annotation	5	MET B 34 ARG B 73 VAL B 80 ALA B 99 TYR B 106	None	0.60A	3qxvD-5vxlB: 20.2	3qxvD-5vxlB: 66.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wb1	ENVELOPE PROTEIN US28, NANOBODY 7 FUSION PROTEIN (Human betaherpesvirus 5; Lama glama)	no annotation	6	VAL A1002 ALA A1024 MET A1034 VAL A1078 ALA A1097 TYR A1107	None	0.93A	3qxvD-5wb1A: 18.1	3qxvD-5wb1A: 15.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5wb2	NANOBODY B1 (synthetic construct)	no annotation	5	ALA D 24 ARG D 72 VAL D 79 ALA D 98 TYR D 118	None	0.91A	3qxvD-5wb2D: 18.8	3qxvD-5wb2D: 68.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5x0t	6H8 FAB FRAGMENT HEAVY CHAIN (Mus musculus)	no annotation	5	ALA A 43 MET A 53 ARG A 93 VAL A 100 TYR A 124	None	0.76A	3qxvD-5x0tA: 19.7	3qxvD-5x0tA: 31.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5x0t	6H8 FAB FRAGMENT HEAVY CHAIN (Mus musculus)	no annotation	5	VAL A 21 MET A 53 ARG A 93 VAL A 100 TYR A 124	None	0.73A	3qxvD-5x0tA: 19.7	3qxvD-5x0tA: 31.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5y9f	HEAVY CHAIN OF FAB FRAGMENT OF ANTIBODY 28F10 (Mus musculus)	no annotation	5	VAL L 2 ALA L 24 MET L 34 ARG L 72 TYR L 112	None	0.96A	3qxvD-5y9fL: 20.0	3qxvD-5y9fL: 57.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	6	SER A 30 MET A 34 ARG A 72 VAL A 79 ALA A 98 TYR A 107	None	1.22A	3qxvD-6dbeA: 20.4	3qxvD-6dbeA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	6	VAL A 2 ALA A 24 MET A 34 VAL A 79 ALA A 98 TYR A 107	None	0.77A	3qxvD-6dbeA: 20.4	3qxvD-6dbeA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	6	VAL A 2 SER A 30 MET A 34 VAL A 79 ALA A 98 TYR A 107	None	1.03A	3qxvD-6dbeA: 20.4	3qxvD-6dbeA: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	5	ALA C 24 MET C 34 ARG C 72 VAL C 79 ALA C 98	None	0.71A	3qxvD-6ehgC: 22.4	3qxvD-6ehgC: 57.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	5	MET C 34 ARG C 72 VAL C 79 ALA C 98 TYR C 112	None	0.61A	3qxvD-6ehgC: 22.4	3qxvD-6ehgC: 57.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	5	VAL C 2 ALA C 24 MET C 34 ARG C 72 VAL C 79	None	0.91A	3qxvD-6ehgC: 22.4	3qxvD-6ehgC: 57.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	5	VAL C 2 MET C 34 ARG C 72 VAL C 79 TYR C 112	None	0.92A	3qxvD-6ehgC: 22.4	3qxvD-6ehgC: 57.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ey0	LLAMA NANOBODY NB01 (Lama glama)	no annotation	5	MET E 34 ARG E 71 VAL E 78 ALA E 94 TYR E 102	None	0.87A	3qxvD-6ey0E: 21.3	3qxvD-6ey0E: 56.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6gzp	NANOBODY (Lama glama)	no annotation	6	VAL A 2 ALA A 24 MET A 34 ARG A 71 ALA A 94 TYR A 102	None	0.79A	3qxvD-6gzpA: 22.1	3qxvD-6gzpA: undetectable

[["3QXV_D_MTXD2000_1","1g6v","Camelus dromedarius","ANTIBODY HEAVY CHAIN","PF07686(V-set)",5,"VAL K 802;ALA K 824;MET K 834;VAL K 877;TYR K 915","None","0.69A","3qxvD-1g6vK:20.1","3qxvD-1g6vK:69.53"],["3QXV_D_MTXD2000_1","1i3u","Lama glama","ANTIBODY VHH LAMA DOMAIN","PF07686(V-set)",5,"ALA A  24;ARG A  77;VAL A  84;ALA A 103;TYR A 118","None;None;None;None;CGN A   1 ( 4.0A)","0.84A","3qxvD-1i3uA:20.8","3qxvD-1i3uA:59.85"],["3QXV_D_MTXD2000_1","1kxt","Camelus dromedarius","IMMUNOGLOBULIN VHH FRAGMENT","PF07686(V-set)",5,"VAL B   2;ALA B  24;MET B  34;ALA B  94;TYR B 102","None","0.98A","3qxvD-1kxtB:19.2","3qxvD-1kxtB:68.75"],["3QXV_D_MTXD2000_1","1pz5","Mus musculus","HEAVY CHAIN OF FAB (SYA\/J6)","PF07654(C1-set);PF07686(V-set)",5,"VAL B   2;ALA B  24;MET B  34;ARG B  71;VAL B  78","None","0.79A","3qxvD-1pz5B:19.9","3qxvD-1pz5B:51.52"],["3QXV_D_MTXD2000_1","1t3q","Pseudomonas putida","QUINOLINE 2-OXIDOREDUCTASE LARGE SUBUNIT","PF01315(Ald_Xan_dh_C);PF02738(Ald_Xan_dh_C2)",5,"ALA B 314;ARG B 416;SER B 354;ARG B 188;VAL B 186","None","0.93A","3qxvD-1t3qB:undetectable","3qxvD-1t3qB:10.68"],["3QXV_D_MTXD2000_1","1t66","Mus musculus","IMMUNOGLOBULIN HEAVY CHAIN","no annotation",5,"ALA H  24;MET H  34;ARG H  74;VAL H  81;TYR H 107","None","0.79A","3qxvD-1t66H:19.3","3qxvD-1t66H:31.43"],["3QXV_D_MTXD2000_1","1t66","Mus musculus","IMMUNOGLOBULIN HEAVY CHAIN","no annotation",5,"VAL H   2;MET H  34;ARG H  74;VAL H  81;TYR H 107","None","0.76A","3qxvD-1t66H:19.3","3qxvD-1t66H:31.43"],["3QXV_D_MTXD2000_1","2x6m","Camelus dromedarius","HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY","PF07686(V-set)",5,"ALA A  24;MET A  34;VAL A  80;ALA A  99;TYR A 115","None","0.66A","3qxvD-2x6mA:21.1","3qxvD-2x6mA:70.54"],["3QXV_D_MTXD2000_1","2xa3","Lama glama","LLAMA HEAVY CHAIN ANTIBODY D7","PF07686(V-set)",5,"SER A  29;MET A  34;VAL A  78;ALA A  94;TYR A 102","SO4 A1114 (-2.7A);None;None;None;None","0.68A","3qxvD-2xa3A:20.8","3qxvD-2xa3A:69.77"],["3QXV_D_MTXD2000_1","3g9a","Camelus dromedarius","MINIMIZER","PF07686(V-set)",7,"VAL B   2;ALA B  24;MET B  34;ARG B  71;VAL B  78;ALA B  94;TYR B 102","None","0.83A","3qxvD-3g9aB:19.5","3qxvD-3g9aB:64.93"],["3QXV_D_MTXD2000_1","3if1","Mus musculus","IMMUNOGLOBULIN HEAVY CHAIN (IGG2A)","PF07654(C1-set);PF07686(V-set)",5,"VAL B   2;ALA B  24;MET B  34;ARG B  71;TYR B 102","None","0.70A","3qxvD-3if1B:19.5","3qxvD-3if1B:32.21"],["3QXV_D_MTXD2000_1","3k7u","Lama glama","ANTIBODY","PF07686(V-set)",5,"MET A  34;ARG A  72;VAL A  79;ALA A  98;TYR A 111","None","0.39A","3qxvD-3k7uA:21.9","3qxvD-3k7uA:73.81"],["3QXV_D_MTXD2000_1","3ln9","Camelidae","IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN B10","PF07686(V-set)",5,"ALA A  24;ARG A  72;VAL A  79;ALA A  98;TYR A 113","None;None;None;None;GOL A 137 (-4.8A)","0.77A","3qxvD-3ln9A:19.2","3qxvD-3ln9A:67.94"],["3QXV_D_MTXD2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",6,"SER A  30;TRP A  34;MET A  36;VAL A  81;ALA A 100;TYR A 120","None","1.48A","3qxvD-3qxuA:24.0","3qxvD-3qxuA:96.03"],["3QXV_D_MTXD2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",7,"SER A  31;TRP A  34;MET A  36;ARG A  74;VAL A  81;ALA A 100;TYR A 120","None","1.40A","3qxvD-3qxuA:24.0","3qxvD-3qxuA:96.03"],["3QXV_D_MTXD2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",7,"VAL A   4;ALA A  26;SER A  30;MET A  36;VAL A  81;ALA A 100;TYR A 120","None","0.90A","3qxvD-3qxuA:24.0","3qxvD-3qxuA:96.03"],["3QXV_D_MTXD2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",8,"VAL A   4;ALA A  26;SER A  31;MET A  36;ARG A  74;VAL A  81;ALA A 100;TYR A 120","None","0.88A","3qxvD-3qxuA:24.0","3qxvD-3qxuA:96.03"],["3QXV_D_MTXD2000_1","3qyc","Homo sapiens","VH DOMAIN OF IGG MOLECULE","PF07686(V-set)",5,"VAL A   4;ALA A  26;MET A  36;ARG A  74;VAL A  81","None","0.69A","3qxvD-3qycA:19.8","3qxvD-3qycA:61.42"],["3QXV_D_MTXD2000_1","3r0m","Lama glama","LLAMA VHH A12","PF07686(V-set)",5,"ALA A  24;SER A  29;MET A  34;VAL A  78;ALA A  94","None;SO4 A 131 (-2.7A);None;None;None","0.94A","3qxvD-3r0mA:21.2","3qxvD-3r0mA:70.54"],["3QXV_D_MTXD2000_1","3stb","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",5,"ALA A  26;MET A  36;ARG A  73;VAL A  80;ALA A  99","None","0.65A","3qxvD-3stbA:22.0","3qxvD-3stbA:70.77"],["3QXV_D_MTXD2000_1","3tpk","Camelidae","IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN KW1","PF07686(V-set)",5,"VAL A   2;ALA A  24;VAL A  79;ALA A  98;TYR A 110","None;BEN A 133 (-3.6A);BEN A 133 (-4.6A);BEN A 133 ( 4.2A);None","0.92A","3qxvD-3tpkA:20.3","3qxvD-3tpkA:64.06"],["3QXV_D_MTXD2000_1","4aq1","Lama glama","NBKB6","PF07686(V-set)",5,"MET B  34;ARG B  72;VAL B  79;ALA B  98;TYR B 113","None","0.97A","3qxvD-4aq1B:21.8","3qxvD-4aq1B:74.19"],["3QXV_D_MTXD2000_1","4b41","Lama glama","ANTIBODY G7","PF07686(V-set)",5,"VAL A   2;ALA A  24;MET A  34;VAL A  78;ALA A  97","None","0.90A","3qxvD-4b41A:18.6","3qxvD-4b41A:72.44"],["3QXV_D_MTXD2000_1","4dka","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",7,"VAL A   2;ALA A  24;MET A  34;ARG A  72;VAL A  79;ALA A  98;TYR A 116","None","0.81A","3qxvD-4dkaA:22.0","3qxvD-4dkaA:73.23"],["3QXV_D_MTXD2000_1","4eig","Lama glama","CA1698 CAMEL ANTIBODY FRAGMENT","PF07686(V-set)",6,"ALA B  24;MET B  34;ARG B  71;VAL B  78;ALA B  97;TYR B 106","None","0.72A","3qxvD-4eigB:20.2","3qxvD-4eigB:66.94"],["3QXV_D_MTXD2000_1","4fhb","Lama glama","NB179","PF07686(V-set)",5,"MET D  34;ARG D  72;VAL D  79;ALA D  98;TYR D 118","None","0.60A","3qxvD-4fhbD:21.2","3qxvD-4fhbD:71.32"],["3QXV_D_MTXD2000_1","4gft","Lama glama","NANOBODY","PF07686(V-set)",5,"MET B  36;ARG B  74;VAL B  81;ALA B 100;TYR B 115","None;None;None;None;PCA B   2 ( 3.9A)","0.38A","3qxvD-4gftB:22.0","3qxvD-4gftB:66.93"],["3QXV_D_MTXD2000_1","4hem","Lama glama","ANTI-BASEPLATE TP901-1 LLAMA VHH 02","PF07686(V-set)",6,"ALA E  24;MET E  34;ARG E  72;VAL E  79;ALA E  98;TYR E 112","None","0.64A","3qxvD-4hemE:22.6","3qxvD-4hemE:73.39"],["3QXV_D_MTXD2000_1","4hlz","Mus musculus","FAB C179 HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL G   2;MET G  34;ARG G  71;VAL G  78;TYR G 102","None","0.78A","3qxvD-4hlzG:19.0","3qxvD-4hlzG:53.91"],["3QXV_D_MTXD2000_1","4hxa","Mus musculus","13D9 FAB HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;MET H  34;ARG H  71;VAL H  78;TYR H 102","None","0.90A","3qxvD-4hxaH:20.6","3qxvD-4hxaH:53.17"],["3QXV_D_MTXD2000_1","4krm","Lama glama","NANOBODY\/VHH DOMAIN 7D12","PF07686(V-set)",6,"ALA B  24;MET B  34;ARG B  72;VAL B  79;ALA B  98;TYR B 113","None","0.71A","3qxvD-4krmB:23.3","3qxvD-4krmB:70.16"],["3QXV_D_MTXD2000_1","4krm","Lama glama","NANOBODY\/VHH DOMAIN 7D12","PF07686(V-set)",5,"SER B  29;MET B  34;VAL B  79;ALA B  98;TYR B 113","None","0.98A","3qxvD-4krmB:23.3","3qxvD-4krmB:70.16"],["3QXV_D_MTXD2000_1","4lde","Lama glama","CAMELID ANTIBODY FRAGMENT","PF07686(V-set)",5,"VAL B   2;ALA B  24;ARG B  71;VAL B  78;TYR B 109","None","0.91A","3qxvD-4ldeB:19.3","3qxvD-4ldeB:68.55"],["3QXV_D_MTXD2000_1","4lde","Lama glama","CAMELID ANTIBODY FRAGMENT","PF07686(V-set)",5,"VAL B   2;MET B  34;ARG B  71;VAL B  78;TYR B 109","None","0.77A","3qxvD-4ldeB:19.3","3qxvD-4ldeB:68.55"],["3QXV_D_MTXD2000_1","4lhq","Vicugna pacos","CAMELID NANOBODY","PF07686(V-set)",5,"ALA B  24;SER B  28;MET B  34;ARG B  72;VAL B  79","None","0.83A","3qxvD-4lhqB:21.5","3qxvD-4lhqB:63.28"],["3QXV_D_MTXD2000_1","4mqt","Lama glama","NANOBODY 9-8","PF07686(V-set)",5,"VAL B   2;ALA B  24;VAL B  82;ALA B 101;TYR B 110","None","0.81A","3qxvD-4mqtB:19.2","3qxvD-4mqtB:64.12"],["3QXV_D_MTXD2000_1","4n1h","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-F11N","PF07686(V-set)",5,"ALA B  24;MET B  34;ARG B  72;VAL B  79;ALA B  98","None","0.81A","3qxvD-4n1hB:21.3","3qxvD-4n1hB:68.50"],["3QXV_D_MTXD2000_1","4nc1","Lama glama","A20.1 VHH","PF07686(V-set)",7,"VAL C   9;ALA C  31;MET C  41;ARG C  79;VAL C  86;ALA C 105;TYR C 119","None","0.90A","3qxvD-4nc1C:22.0","3qxvD-4nc1C:70.23"],["3QXV_D_MTXD2000_1","4nc2","Lama glama","B39 VHH","PF07686(V-set)",5,"ALA B  24;MET B  34;ARG B  71;ALA B  97;TYR B 111","None","0.75A","3qxvD-4nc2B:22.8","3qxvD-4nc2B:70.16"],["3QXV_D_MTXD2000_1","4nc2","Lama glama","B39 VHH","PF07686(V-set)",5,"VAL B   2;MET B  34;ARG B  71;ALA B  97;TYR B 111","None","0.63A","3qxvD-4nc2B:22.8","3qxvD-4nc2B:70.16"],["3QXV_D_MTXD2000_1","4p2c","Lama glama","NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",6,"VAL G   2;MET G  34;ARG G  71;VAL G  78;ALA G  97;TYR G 111","None","0.62A","3qxvD-4p2cG:19.1","3qxvD-4p2cG:70.97"],["3QXV_D_MTXD2000_1","4p49","Gallus gallus","ANTIBODY SCFV B8","PF07686(V-set)",5,"VAL A 122;ALA A 144;MET A 154;ARG A 193;VAL A 200","None","0.91A","3qxvD-4p49A:21.7","3qxvD-4p49A:51.88"],["3QXV_D_MTXD2000_1","4pb0","Mus musculus","AB53 HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;ALA H  24;MET H  34;ARG H  71;VAL H  78"," CL H 303 (-4.4A);None;None;None;None","0.93A","3qxvD-4pb0H:18.7","3qxvD-4pb0H:32.26"],["3QXV_D_MTXD2000_1","4qlr","Lama glama","LLAMA NANOBODY N02 VH DOMAIN","PF07686(V-set)",5,"ALA A  24;ARG A  72;VAL A  79;ALA A  98;TYR A 113","None","0.76A","3qxvD-4qlrA:22.4","3qxvD-4qlrA:69.84"],["3QXV_D_MTXD2000_1","4qo1","Lama glama","NB139 NANOBODY AGAINST THE DNA-BINDING DOMAIN OF P53","PF07686(V-set)",6,"ALA A  25;MET A  35;ARG A  73;VAL A  80;ALA A  99;TYR A 113","None","0.57A","3qxvD-4qo1A:21.2","3qxvD-4qo1A:62.70"],["3QXV_D_MTXD2000_1","4tvs","Vicugna pacos","VHH DOMAIN BS-1","PF05609(LAP1C)",5,"ALA a  25;ARG a  73;VAL a  80;ALA a  99;TYR a 117","None","0.79A","3qxvD-4tvsa:22.1","3qxvD-4tvsa:72.87"],["3QXV_D_MTXD2000_1","4w6y","Lama glama","NANOBODY NBFEDF9","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;VAL B  79;ALA B  98;TYR B 118","None","0.92A","3qxvD-4w6yB:21.0","3qxvD-4w6yB:69.47"],["3QXV_D_MTXD2000_1","4weu","Lama glama","ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",6,"VAL D 802;ALA D 824;MET D 834;ARG D 872;ALA D 898;TYR D 910","None","0.68A","3qxvD-4weuD:22.3","3qxvD-4weuD:72.00"],["3QXV_D_MTXD2000_1","4x8j","Mus musculus","12F4 FAB HEAVY CHAIN","no annotation",5,"VAL H   2;MET H  34;ARG H  74;VAL H  81;TYR H 104","None;None;None;None;2PE H 302 ( 4.6A)","0.67A","3qxvD-4x8jH:15.5","3qxvD-4x8jH:33.82"],["3QXV_D_MTXD2000_1","4xt1","Vicugna pacos","NANOBODY 7","PF07686(V-set)",6,"VAL C   2;ALA C  24;MET C  34;VAL C  78;ALA C  97;TYR C 107","None","0.87A","3qxvD-4xt1C:19.0","3qxvD-4xt1C:68.75"],["3QXV_D_MTXD2000_1","5a2k","Mus musculus","IG LAMBDA-1 CHAIN V REGION S43","PF07686(V-set)",6,"VAL H   2;ALA H  24;MET H  34;ARG H  71;VAL H  78;TYR H 102","None","0.79A","3qxvD-5a2kH:19.8","3qxvD-5a2kH:29.03"],["3QXV_D_MTXD2000_1","5aum","Rattus","HEAVY CHAIN OF FAB FRAGMENT","no annotation",5,"ALA H  24;MET H  34;ARG H  71;VAL H  78;ALA H  94","None","0.67A","3qxvD-5aumH:19.7","3qxvD-5aumH:38.16"],["3QXV_D_MTXD2000_1","5aum","Rattus","HEAVY CHAIN OF FAB FRAGMENT","no annotation",5,"VAL H   2;MET H  34;ARG H  71;VAL H  78;ALA H  94","None","0.58A","3qxvD-5aumH:19.7","3qxvD-5aumH:38.16"],["3QXV_D_MTXD2000_1","5e1h","Vicugna pacos","F8(JOB10) VHH ANTIBODY","PF07686(V-set)",5,"VAL B   2;ALA B  24;MET B  34;ARG B  72;VAL B  79","None","0.83A","3qxvD-5e1hB:20.3","3qxvD-5e1hB:68.75"],["3QXV_D_MTXD2000_1","5e7f","Camelus dromedarius","NANOBODY L06","PF07686(V-set)",5,"VAL A   4;MET A  36;ARG A  73;VAL A  80;ALA A  99","None","0.72A","3qxvD-5e7fA:18.4","3qxvD-5e7fA:66.93"],["3QXV_D_MTXD2000_1","5fwo","Lama glama","NANOBODY","PF07686(V-set)",6,"VAL A   2;ALA A  24;MET A  34;ARG A  71;VAL A  78;TYR A 102","None","0.87A","3qxvD-5fwoA:21.5","3qxvD-5fwoA:68.18"],["3QXV_D_MTXD2000_1","5fwo","Lama glama","NANOBODY","PF07686(V-set)",6,"VAL A   2;MET A  34;ARG A  71;VAL A  78;ALA A  94;TYR A 102","None","0.62A","3qxvD-5fwoA:21.5","3qxvD-5fwoA:68.18"],["3QXV_D_MTXD2000_1","5gxb","Vicugna pacos","NANOBODY","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;VAL B  79;ALA B  98;TYR B 118","None","1.09A","3qxvD-5gxbB:20.9","3qxvD-5gxbB:68.42"],["3QXV_D_MTXD2000_1","5hm1","Lama glama","LAMA VHH ANTIBODY 2E7","PF07686(V-set)",5,"VAL A   2;ALA A  24;VAL A  78;ALA A  94;TYR A 102","None","0.69A","3qxvD-5hm1A:18.7","3qxvD-5hm1A:68.00"],["3QXV_D_MTXD2000_1","5hvf","Vicugna pacos","VHH-I83","PF07686(V-set)",6,"VAL B   2;ALA B  24;ARG B  70;VAL B  77;ALA B  96;TYR B 108","None","0.86A","3qxvD-5hvfB:18.5","3qxvD-5hvfB:69.35"],["3QXV_D_MTXD2000_1","5hvf","Vicugna pacos","VHH-I83","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;VAL B  77;ALA B  96;TYR B 108","None","0.95A","3qxvD-5hvfB:18.5","3qxvD-5hvfB:69.35"],["3QXV_D_MTXD2000_1","5iml","Camelidae","NANOBODY","PF07686(V-set)",6,"ALA B  23;MET B  33;ARG B  71;VAL B  78;ALA B  97;TYR B 113","None","0.75A","3qxvD-5imlB:23.6","3qxvD-5imlB:75.40"],["3QXV_D_MTXD2000_1","5j1s","Vicugna pacos","VHH DOMAIN BS-2","PF07686(V-set)",7,"VAL C   3;ALA C  25;MET C  35;ARG C  72;VAL C  79;ALA C  98;TYR C 112","None","0.88A","3qxvD-5j1sC:19.5","3qxvD-5j1sC:66.17"],["3QXV_D_MTXD2000_1","5j56","Vicugna pacos","VHH SINGLE CHAIN ANTIBODY V1C7","PF07686(V-set)",6,"VAL B   2;ALA B  24;ARG B  76;VAL B  83;ALA B 102;TYR B 117","None","0.91A","3qxvD-5j56B:20.7","3qxvD-5j56B:67.18"],["3QXV_D_MTXD2000_1","5ja9","Lama glama","NANOBODY 6","PF07686(V-set)",5,"VAL A   3;ALA A  25;MET A  35;ARG A  73;ALA A  99","None","0.93A","3qxvD-5ja9A:20.2","3qxvD-5ja9A:68.55"],["3QXV_D_MTXD2000_1","5jqh","Lama glama","NANOBODY60, NB60","no annotation",5,"VAL D   2;MET D  34;ARG D  71;VAL D  78;ALA D  97","None","0.95A","3qxvD-5jqhD:19.2","3qxvD-5jqhD:70.16"],["3QXV_D_MTXD2000_1","5kel","Homo sapiens","C2G4 VARIABLE FAB DOMAIN HEAVY CHAIN","PF07686(V-set)",6,"VAL H   2;ALA H  24;MET H  34;ARG H  71;VAL H  78;TYR H 102","None","0.99A","3qxvD-5kelH:17.1","3qxvD-5kelH:51.15"],["3QXV_D_MTXD2000_1","5lhq","Vicugna pacos","CAMELID-DERIVED ANTIBODY FRAGMENT NB7","PF07686(V-set)",6,"VAL B   2;ALA B  24;ARG B  72;VAL B  79;ALA B  98;TYR B 122","None","0.62A","3qxvD-5lhqB:21.6","3qxvD-5lhqB:64.66"],["3QXV_D_MTXD2000_1","5lmj","Lama glama","NANOBODY","PF07686(V-set)",6,"ALA A  24;MET A  34;ARG A  71;VAL A  78;ALA A  94;TYR A 102","None","0.95A","3qxvD-5lmjA:20.2","3qxvD-5lmjA:73.23"],["3QXV_D_MTXD2000_1","5lmj","Lama glama","NANOBODY","PF07686(V-set)",6,"VAL A   2;ALA A  24;ARG A  71;VAL A  78;ALA A  94;TYR A 102","None","0.95A","3qxvD-5lmjA:20.2","3qxvD-5lmjA:73.23"],["3QXV_D_MTXD2000_1","5lwf","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S","no annotation",6,"ALA C  27;MET C  37;ARG C  75;VAL C  82;ALA C 101;TYR C 117","None;None;None;None;None;ACT C 202 (-4.4A)","0.59A","3qxvD-5lwfC:21.3","3qxvD-5lwfC:68.80"],["3QXV_D_MTXD2000_1","5lwf","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S","no annotation",5,"VAL C   5;ARG C  75;VAL C  82;ALA C 101;TYR C 117","None;None;None;None;ACT C 202 (-4.4A)","0.86A","3qxvD-5lwfC:21.3","3qxvD-5lwfC:68.80"],["3QXV_D_MTXD2000_1","5m13","synthetic construct","SYNTHETIC NANOBODY L2_C06 (A-MBP#2)","no annotation",5,"VAL B   2;ALA B  24;VAL B  79;ALA B  98;TYR B 114","None","0.93A","3qxvD-5m13B:21.8","3qxvD-5m13B:63.64"],["3QXV_D_MTXD2000_1","5mwn","Lama glama","LLAMA NANOBODY RAISED AGAINST TSSK, NBK27","PF07686(V-set)",5,"VAL N   2;ALA N  24;ARG N  71;VAL N  78;ALA N  97","None","0.94A","3qxvD-5mwnN:18.3","3qxvD-5mwnN:67.46"],["3QXV_D_MTXD2000_1","5mwn","Lama glama","LLAMA NANOBODY RAISED AGAINST TSSK, NBK27","PF07686(V-set)",5,"VAL N   2;ALA N  24;MET N  34;VAL N  78;ALA N  97","None","0.95A","3qxvD-5mwnN:18.3","3qxvD-5mwnN:67.46"],["3QXV_D_MTXD2000_1","5o02","Vicugna pacos","NANOBODY (VHH) NANO-4","PF07686(V-set)",5,"VAL C   2;MET C  34;ARG C  72;ALA C  98;TYR C 113","None","0.66A","3qxvD-5o02C:21.3","3qxvD-5o02C:68.55"],["3QXV_D_MTXD2000_1","5o03","Norwalk virus","NANOBODY (VHH) NANO-32","PF07686(V-set)",5,"ALA C  24;ARG C  72;VAL C  79;ALA C  98;TYR C 124","None","0.88A","3qxvD-5o03C:20.3","3qxvD-5o03C:63.70"],["3QXV_D_MTXD2000_1","5o04","Vicugna pacos","NANOBODY (VHH) NANO-26","PF07686(V-set)",5,"VAL E   2;ALA E  24;ARG E  71;VAL E  78;TYR E 104","None","0.83A","3qxvD-5o04E:18.7","3qxvD-5o04E:65.32"],["3QXV_D_MTXD2000_1","5o05","Vicugna pacos","NANOBODY (VHH) NANO-42","PF07686(V-set)",5,"VAL C   2;ALA C  24;SER C  29;VAL C  78;TYR C 109","None","0.90A","3qxvD-5o05C:17.1","3qxvD-5o05C:67.20"],["3QXV_D_MTXD2000_1","5o8f","Lama glama","NANOBODY NB25","no annotation",5,"MET L  34;ARG L  72;VAL L  79;ALA L  98;TYR L 114","None","0.62A","3qxvD-5o8fL:21.4","3qxvD-5o8fL:68.46"],["3QXV_D_MTXD2000_1","5uk4","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",6,"VAL p   2;MET p  34;ARG p  72;VAL p  79;ALA p  98;TYR p 114","None","0.76A","3qxvD-5uk4p:21.4","3qxvD-5uk4p:71.43"],["3QXV_D_MTXD2000_1","5ukb","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",5,"ALA d  24;ARG d  72;VAL d  79;ALA d  98;TYR d 113","None","0.74A","3qxvD-5ukbd:22.3","3qxvD-5ukbd:70.97"],["3QXV_D_MTXD2000_1","5vgj","Homo sapiens","VRC38.01 FAB HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;ALA H  24;MET H  34;ARG H  71;VAL H  78","None","0.69A","3qxvD-5vgjH:19.1","3qxvD-5vgjH:36.45"],["3QXV_D_MTXD2000_1","5vxj","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JMK-E3","no annotation",6,"VAL B   2;MET B  34;ARG B  72;VAL B  79;ALA B  98;TYR B 108","None","0.78A","3qxvD-5vxjB:19.2","3qxvD-5vxjB:63.08"],["3QXV_D_MTXD2000_1","5vxl","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JPS-G3","no annotation",5,"ALA B  24;MET B  34;ARG B  73;ALA B  99;TYR B 106","None","0.69A","3qxvD-5vxlB:20.2","3qxvD-5vxlB:66.41"],["3QXV_D_MTXD2000_1","5vxl","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JPS-G3","no annotation",5,"MET B  34;ARG B  73;VAL B  80;ALA B  99;TYR B 106","None","0.60A","3qxvD-5vxlB:20.2","3qxvD-5vxlB:66.41"],["3QXV_D_MTXD2000_1","5wb1","Human betaherpesvirus 5;Lama glama","ENVELOPE PROTEIN US28, NANOBODY 7 FUSION PROTEIN","no annotation",6,"VAL A1002;ALA A1024;MET A1034;VAL A1078;ALA A1097;TYR A1107","None","0.93A","3qxvD-5wb1A:18.1","3qxvD-5wb1A:15.08"],["3QXV_D_MTXD2000_1","5wb2","synthetic construct","NANOBODY B1","no annotation",5,"ALA D  24;ARG D  72;VAL D  79;ALA D  98;TYR D 118","None","0.91A","3qxvD-5wb2D:18.8","3qxvD-5wb2D:68.29"],["3QXV_D_MTXD2000_1","5x0t","Mus musculus","6H8 FAB FRAGMENT HEAVY CHAIN","no annotation",5,"ALA A  43;MET A  53;ARG A  93;VAL A 100;TYR A 124","None","0.76A","3qxvD-5x0tA:19.7","3qxvD-5x0tA:31.40"],["3QXV_D_MTXD2000_1","5x0t","Mus musculus","6H8 FAB FRAGMENT HEAVY CHAIN","no annotation",5,"VAL A  21;MET A  53;ARG A  93;VAL A 100;TYR A 124","None","0.73A","3qxvD-5x0tA:19.7","3qxvD-5x0tA:31.40"],["3QXV_D_MTXD2000_1","5y9f","Mus musculus","HEAVY CHAIN OF FAB FRAGMENT OF ANTIBODY 28F10","no annotation",5,"VAL L   2;ALA L  24;MET L  34;ARG L  72;TYR L 112","None","0.96A","3qxvD-5y9fL:20.0","3qxvD-5y9fL:57.94"],["3QXV_D_MTXD2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",6,"SER A  30;MET A  34;ARG A  72;VAL A  79;ALA A  98;TYR A 107","None","1.22A","3qxvD-6dbeA:20.4","3qxvD-6dbeA:undetectable"],["3QXV_D_MTXD2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",6,"VAL A   2;ALA A  24;MET A  34;VAL A  79;ALA A  98;TYR A 107","None","0.77A","3qxvD-6dbeA:20.4","3qxvD-6dbeA:undetectable"],["3QXV_D_MTXD2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",6,"VAL A   2;SER A  30;MET A  34;VAL A  79;ALA A  98;TYR A 107","None","1.03A","3qxvD-6dbeA:20.4","3qxvD-6dbeA:undetectable"],["3QXV_D_MTXD2000_1","6ehg","Lama glama","HC3NB1","no annotation",5,"ALA C  24;MET C  34;ARG C  72;VAL C  79;ALA C  98","None","0.71A","3qxvD-6ehgC:22.4","3qxvD-6ehgC:57.14"],["3QXV_D_MTXD2000_1","6ehg","Lama glama","HC3NB1","no annotation",5,"MET C  34;ARG C  72;VAL C  79;ALA C  98;TYR C 112","None","0.61A","3qxvD-6ehgC:22.4","3qxvD-6ehgC:57.14"],["3QXV_D_MTXD2000_1","6ehg","Lama glama","HC3NB1","no annotation",5,"VAL C   2;ALA C  24;MET C  34;ARG C  72;VAL C  79","None","0.91A","3qxvD-6ehgC:22.4","3qxvD-6ehgC:57.14"],["3QXV_D_MTXD2000_1","6ehg","Lama glama","HC3NB1","no annotation",5,"VAL C   2;MET C  34;ARG C  72;VAL C  79;TYR C 112","None","0.92A","3qxvD-6ehgC:22.4","3qxvD-6ehgC:57.14"],["3QXV_D_MTXD2000_1","6ey0","Lama glama","LLAMA NANOBODY NB01","no annotation",5,"MET E  34;ARG E  71;VAL E  78;ALA E  94;TYR E 102","None","0.87A","3qxvD-6ey0E:21.3","3qxvD-6ey0E:56.60"],["3QXV_D_MTXD2000_1","6gzp","Lama glama","NANOBODY","no annotation",6,"VAL A   2;ALA A  24;MET A  34;ARG A  71;ALA A  94;TYR A 102","None","0.79A","3qxvD-6gzpA:22.1","3qxvD-6gzpA:undetectable"]]